A Game-Changer by Roche and Chugai | NXT007: For Hemophilia A, Without Inhibitors
The National Bleeding Disorders Foundation (NBDF) posted in appreciation of Roche and Chugai on X:
”Roche and Chugai recently presented new data on NXT007, an investigational bispecific antibody therapy for people with hemophilia A without inhibitors. Phase III studies are planned to begin in 2026.”
To learn more about this advancement, follow the link.
The promising findings—because we can never have too many early-stage breakthroughs—were shared during recent scientific presentations, hinting at NXT007’s potential to once again reshape prophylactic treatment for this ever-hopeful patient population.
Roche and Chugai have recently unveiled new data on NXT007, an investigational bispecific antibody therapy designed for individuals with hemophilia A without inhibitors.
NXT007, engineered to mimic the function of activated factor VIII, builds upon the success of emicizumab and is designed to offer improved pharmacokinetics and efficacy.
Looking ahead, Phase III clinical trials of NXT007 are expected to begin in 2026, marking a significant step forward in evaluating the therapy’s long-term potential and its role in reducing bleeding episodes and improving quality of life for patients!
Find more on drug advancements in the field of Hemophilia management in Hemostasis Today.
-
Aug 7, 2026, 07:43Martin Tøffner Pedersen: Reducing False-Negative Results in Transfusion Testing
-
Aug 7, 2026, 07:16Francisco Chacón-Lozsán: Does Tranexamic Acid Still Have a Role in Gastrointestinal Bleeding?
-
Aug 7, 2026, 06:05Helping Families Navigate Hemophilia Through Genetic Testing – EAHAD
-
Aug 7, 2026, 05:50Nasib Ali: The Future of Digital Morphology and AI in Clinical Haematology
-
Aug 6, 2026, 23:22Deborah Siega: What Predicts Bleeding in Anticoagulated Patients
-
Aug 6, 2026, 18:11Filipe Gonçalves: Are DOACs Truly Pharmacokinetically Predictable or Simply Pharmacodynamically Forgiving?
-
Aug 6, 2026, 18:04Wolfgang Miesbach: Base Editing Expands Therapeutic Targets for Hemophilia B
-
Aug 6, 2026, 18:03Identifing Gaps in How IDA is Recognised and Managed in Children – ISBT
-
Aug 6, 2026, 18:03Expanding Access to Care for People With Hemophilia in Côte d’Ivoire – WFH